Pliant Therapeutics, Inc.

NEWS
Two months after unveiling a new approach to identify novel biomarkers for the detection and treatment of idiopathic pulmonary fibrosis, South San Francisco-based Pliant Therapeutics secured $62 million in a Series B financing round to support its research programs.
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
AWARDS
  • NextGen Class of 2017
JOBS
IN THE PRESS